The effect of psilocybin and eugenol in dextran and lipopolysaccharide induced gastro-intestinal inflammation

Inflammatory bowel disease (IBD) is a complex gastrointestinal condition, arising from immune dysfunction, epithelial cell abnormalities, and gut microbiota imbalances. This study seeks to find the potential anti-inflammatory properties of psilocybin and eugenol in both local and systemic intestinal inflammation by utilizing a murine model of IBD induced by dextran sulfate sodium (DSS) and lipopolysaccharide (LPS). We evaluated the impact of these compounds on inflammatory cytokine levels in intestinal tissues and also explored changes in serotonin receptor (HTR2A and B) expression, and transient receptor potential (TRP) ion channels (TRP1 and TRPM8), analyzing the influence of these compounds on serotonin signaling pathways. Our study yielded significant insights into the multifaceted world of inflammation within the gastrointestinal tract. Notably, our findings revealed intriguing disparities in the trends observed pre- and post-treatment, particularly in the context of small and large intestine inflammation induced by LPS and DSS. Additionally, our study unearthed evidence of the anti-inflammatory properties of psilocybin and eugenol, compounds with agonistic effects on serotonin and TRP channels. Most notably, we observed a synergistic effect when these compounds were combined. More comprehensive studies on the medicinal effects of natural compounds in IBD animal models are pivotal for exploring their implications, specifically the analysis of drug-microbiota-immune system interactions.

Authors

• Asghari, Zeinab
• University of Lethbridge. Faculty of Arts and Science

• inflammatory bowel disease
• psilocybin
• eugenol
• anti-inflammatories
• dextran sulfate sodium model
• lipopolysaccharide model

Identifier

hdl:10133/6728

OAI identifier oai:identifier

oai:opus.uleth.ca:10133/6728